Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination

Addiction

Volumn 94, Issue 4, 1999, Pages 489-493

  Borg, Lisa ^a   Khuri, Elizabeth ^b   Wells, Aaron ^b   Melia, Dorothy ^b   Bergasa, Nora V ^a   Ho, Ann ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; MEMBRANE ANTIGEN; METHADONE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; HEPATITIS B; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INTRAVENOUS DRUG ABUSE; MALE; METHADONE TREATMENT; TIME; VACCINATION;

EID: 0032924858     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-0443.1999.9444894.x     Document Type: Article

References (26)

1. American Academy of Pediatrics Committee on Infectious Diseases (1992) Universal hepatitis B immunization, Pediatrics, 89, 795-800.
2. American Liver Foundation (1996) Fact Sheet (Cedar Grove NJ, American Liver Foundation).
3. Borg, L., Khuri, E., Wells, A. et al. (1995) Hepatitis B vaccination of methadone maintained former heroin addicts is effective, Hepatology, 22, 324.
4. Borg, L., Khuri, E., Wells, A. et al. (1996a) Hepatitis B vaccination of methadone maintained patients: a pilot study, NIDA Research Monograph Series, 162, 191.
5. Borg, L., Khuri, E., Wells, A. et al. (1996b) Methadone maintained former heroin addicts including those who are anti-HIV-1 positive comply with and respond to hepatitis B vaccination, Abstract for the Fourth Annual Symposium on AIDS, Drugs of Abuse and the Neuroimmune Axis, 22.
6. Centers for Disease Control (CDC) (1990) Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP), Morbidity and Mortality Weekly Report, 39, 5-22.
7. Centers for Disease Control (CDC) (1991) Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination, Mortality and Morbidity Weekly Report, 40(RR-13), 1-19.
8. Collier, A. C., Corey, L., Murphy, V. L. & Handsfield, H. H. (1988) Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination, Annals of Internal Medicine, 109, 101-105.
9. Craven, D. E., Awdeh, Z. L., Kunches, L. M. et al. (1986) Nonresponsiveness to hepatitis B vaccine in health care workers, Annals of Internal Medicine, 105, 356-360.
10. Dienstag, J. L., Werner, B. G. & Polk, F. (1984) Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy, Annals of Internal Medicine, 101, 34-40.
11. Fabrizi, F., Di Filippo, S., Marcelli, D. (1996) Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost effectiveness analysis, Nephron, 72, 536-543.
12. Goilav, C. & Piot, P. (1989) Vaccination against hepatitis B in homosexual men, American Journal of Medicine, 87 (suppl. 3A), 21S-25S.
13. Kane, M. A. (1995) Global programme for control of hepatitis B infection, Vaccine, 13 (suppl. 1), S47-49.
14. Kreek, M. J., Dodes, L., Kane, S., Knobler, J. & Martin, R. (1972) Long-term methadone maintenance therapy: effects on liver function, Annals of Internal Medicine, 77, 598-602.
15. Kreek, M. J. (1978) Medical complications in methadone patients, Annals of the New York Academy of Science, 311, 110-134.
16. Kreek, M. J., Des Jarlais, D. C., Trepo, C. L., Novick, D. M., Abdul-Quader, A. & Raghunath, J. (1990) Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS, Journal of Infectious Diseases, 162, 538-541.
17. Kunches, L. M., Craven, D. E. & Werner, B. G. (1986) Seroprevalence of hepatitis B virus and delta agent in parenteral drug abusers, American Journal of Medicine, 81, 591-594.
18. Miller, D. J., Kleber, H. & Bloomer, J. R. (1979) Chronic hepatitis associated with drug abuse: significance of hepatitis B virus, Yale Journal of Biology and Medicine, 52, 135-140.
19. Novick, D. M., Gelb, A. M., Stenger, R. J. et al. (1981) Hepatitis B serologic studies in narcotic users with chronic liver diseases, American Journal of Gastroenterology, 75, 111-115.
20. Roure, C. (1995) Overview of epidemiology and disease burden of hepatitis B in the European region, Vaccine, 13 (suppl. 1), S18-21.
21. Rumi, M., Colombo, M., Romeo, R. et al. (1991) Suboptimal response to hepatitis B vaccine in drug users, Archives of Internal Medicine, 151, 574-578.
22. Schalm, S. W., Heytink, R. A., Mannaerts, H. & Vreungdenhil, A. (1983) Immune response to hepatitis B vaccine in drug addicts, Journal of Infection, 7(suppl. ), 41-45.
23. Stevens, C. E., Alter, H. J., Taylor, P. E., Zang, E. A., Harley, E. J. & Szmuness, W. (1984) The Dialysis Vaccine Trial Study Group, New England Journal of Medicine, 311, 496-501.
24. Van Damme, P., Kane, M. & Meheus, A. (1997) Integration of hepatitis B vaccine into national immunisation programmes, British Medical Journal, 314, 1033-1036.
25. + lymphocyte count and vaccination schedule, International Journal of STD and AIDS, 7, 490-494.
26. World Health Organization (1992) Expanded programme on immunization global advisory group, Weekly Epidemiology Record, 3, 11-16.